Keytruda receives accelerated approval from FDA for locally recurrent, unresectable or metastatic TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Keytruda (pembrolizumab) received accelerated approval from FDA in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test.

Keytruda is sponsored by Merck.

FDA also approved the PD-L1 IHC 22C3 pharmDx (sponsored by Dako North America Inc.) as a companion diagnostic for selecting patients with TNBC for pembrolizumab.

Approval was based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial in patients with locally recurrent unresectable or metastatic TNBC, who had not been previously treated with chemotherapy in the metastatic setting. Patients were randomized (2:1) to receive pembrolizumab 200 mg on day one every every weeks or placebo in combination with different chemotherapy treatments (paclitaxel protein-bound, or paclitaxel, or gemcitabine plus carboplatin) via intravenous infusion.

The main efficacy outcome measure was progression-free survival as assessed by blinded independent review according to RECIST 1.1, tested in the subgroup of patients with CPS ≥10. Median PFS was 9.7 months (95% CI: 7.6, 11.3) in the pembrolizumab plus chemotherapy arm and 5.6 months (95% CI:5.3, 7.5) in the placebo arm (HR 0.65; 95% CI: 0.49, 0.86; one-sided p-value=0.0012).

Table of Contents

YOU MAY BE INTERESTED IN

Login